CN108348509A - 用于治疗增殖减少性病症的化合物 - Google Patents

用于治疗增殖减少性病症的化合物 Download PDF

Info

Publication number
CN108348509A
CN108348509A CN201680063630.0A CN201680063630A CN108348509A CN 108348509 A CN108348509 A CN 108348509A CN 201680063630 A CN201680063630 A CN 201680063630A CN 108348509 A CN108348509 A CN 108348509A
Authority
CN
China
Prior art keywords
substituent
group
compound
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680063630.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·弗吕加勒
L·约翰逊
T·伦德贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lu Licensing Co
Original Assignee
Lu Licensing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lu Licensing Co filed Critical Lu Licensing Co
Publication of CN108348509A publication Critical patent/CN108348509A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680063630.0A 2015-11-03 2016-11-03 用于治疗增殖减少性病症的化合物 Pending CN108348509A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1551419-3 2015-11-03
SE1551419 2015-11-03
PCT/EP2016/076550 WO2017076968A1 (en) 2015-11-03 2016-11-03 Compounds for treatment of hypoproliferative disorders

Publications (1)

Publication Number Publication Date
CN108348509A true CN108348509A (zh) 2018-07-31

Family

ID=57326350

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063630.0A Pending CN108348509A (zh) 2015-11-03 2016-11-03 用于治疗增殖减少性病症的化合物

Country Status (10)

Country Link
US (1) US11471446B2 (https=)
EP (1) EP3370720A1 (https=)
JP (1) JP6977238B2 (https=)
KR (1) KR20180073600A (https=)
CN (1) CN108348509A (https=)
AU (1) AU2016348659B2 (https=)
BR (1) BR112018008931A8 (https=)
IL (1) IL258593B (https=)
MX (1) MX390651B (https=)
WO (1) WO2017076968A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
WO2024193640A1 (zh) * 2023-03-22 2024-09-26 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
CA3128377A1 (en) * 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
US20220226343A1 (en) * 2019-05-21 2022-07-21 University Of South Carolina 3-amino-4-[4-[4 (dimethylcarbamoyl) phenyl]-1,4-diazepan-1-yl]thieno[2,3-b]pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same
GB202208226D0 (en) * 2022-06-06 2022-07-20 Royal Veterinary College Method and treatment for osteoarthritis and diseases of chondrocyte hypertrophy
TW202449143A (zh) * 2023-04-18 2024-12-16 國立大學法人京都大學 第2型先天性淋巴細胞之製造方法
WO2026004819A1 (ja) * 2024-06-24 2026-01-02 国立大学法人 長崎大学 骨形成促進用組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649581A (zh) * 2002-06-06 2005-08-03 贝林格尔.英格海姆药物公司 取代的3－氨基－噻吩并[2,3－b]吡啶－2－羧酸酰胺化合物及其制备方法和用途
WO2013138101A2 (en) * 2012-03-16 2013-09-19 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
CN104363913A (zh) * 2012-02-02 2015-02-18 申内克斯生物科技公司 Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
CN104903321A (zh) * 2012-11-08 2015-09-09 赛尔维他股份公司 作为激酶抑制剂的经取代三环苯并咪唑
WO2015144290A1 (en) * 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005233437A1 (en) 2004-04-12 2005-10-27 Sankyo Company, Limited Thienopyridine derivatives
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
US20140309224A1 (en) * 2011-09-13 2014-10-16 Roninson Igor B TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
EP2888232A1 (en) 2012-08-23 2015-07-01 F. Hoffmann-La Roche AG Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
JP2016501251A (ja) 2012-12-10 2016-01-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための新規二環フェニル−ピリジン／ピラジン
WO2014106606A1 (en) 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014154723A1 (en) 2013-03-29 2014-10-02 F. Hoffmann-La Roche Ag Novel pyrrole derivatives for the treatment of cancer
WO2014194245A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649581A (zh) * 2002-06-06 2005-08-03 贝林格尔.英格海姆药物公司 取代的3－氨基－噻吩并[2,3－b]吡啶－2－羧酸酰胺化合物及其制备方法和用途
CN104363913A (zh) * 2012-02-02 2015-02-18 申内克斯生物科技公司 Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
WO2013138101A2 (en) * 2012-03-16 2013-09-19 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
CN104903321A (zh) * 2012-11-08 2015-09-09 赛尔维他股份公司 作为激酶抑制剂的经取代三环苯并咪唑
WO2015144290A1 (en) * 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHENG WEI ET AL.: "Lenalidomide Promotes p53 Degradation by Inhibiting MDM2 Auto-ubiquitination in Myelodysplastic Syndrome with Chromosome 5q Deletion", 《ONCOGENE》 *
STEFANO FUMAGALLI ET AL.: "The Role of p53 in Ribosomopathies", 《SEMINARS IN HEMATOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
WO2024193640A1 (zh) * 2023-03-22 2024-09-26 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Also Published As

Publication number Publication date
US20190111034A1 (en) 2019-04-18
AU2016348659A1 (en) 2018-05-31
BR112018008931A8 (pt) 2019-02-26
CA3002495A1 (en) 2017-05-11
EP3370720A1 (en) 2018-09-12
JP2018532784A (ja) 2018-11-08
AU2016348659B2 (en) 2022-07-28
IL258593B (en) 2021-04-29
IL258593A (en) 2018-06-28
WO2017076968A1 (en) 2017-05-11
JP6977238B2 (ja) 2021-12-08
BR112018008931A2 (pt) 2018-11-06
KR20180073600A (ko) 2018-07-02
MX2018005158A (es) 2019-05-16
US11471446B2 (en) 2022-10-18
MX390651B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
CN108348509A (zh) 用于治疗增殖减少性病症的化合物
AU2023266373B2 (en) Kv7 channel activators compositions and methods of use
JP6640222B2 (ja) ヘテロ環式誘導体およびその使用
US10532999B2 (en) 6-substituted quinazolinone inhibitors
CA2804069C (en) Pyrazoloquinolines
JP2017538676A (ja) ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤
EA029017B1 (ru) ДВОЙНЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ PI3-КИНАЗ δ И γ
EP2906564B1 (en) Treating brain cancer using agelastatin a (aa) and analogues thereof
JP2009539936A (ja) ピラゾロピリミドン
EP3006442A1 (en) Conjugate of benzofuranone and indole or azaindole, and preparation and uses thereof
JP2003514850A (ja) 薬剤を調製するためのインジルビン誘導体の使用
WO2019089577A1 (en) Small molecule inhibitors of cancer stem cells and mesenchymal cancer types
EP2279750A1 (en) Aniline derivative having anti-rna viral activity
JP2009542777A (ja) ベンゾピラノピラゾール
WO2004060400A1 (ja) 上皮成長因子受容体を分子標的とする抗精神病薬
CA3192071A1 (en) Compositions and methods for treating muscular dystrophies
CN106632091B (zh) 喹唑啉化合物在调控神经干细胞增殖和分化中的应用
CA3002495C (en) Compounds for treatment of hypoproliferative disorders
JP2008528552A (ja) 新規のインドロピリジン、ベンゾフラノピリジン及びベンゾチエノピリジン
EA049776B1 (ru) Композиции и способы для лечения мышечных дистрофий
JP2008528551A (ja) インドロピリジン、ベンゾフラノピリジン及びベンゾチエノピリジン
HK1186736A1 (en) (e)-n-(2-amino-phenyl)-3-{1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]-1h-pyrrol-3-yl}-acrylamide tosylate salt
HK1186736B (en) (e)-n-(2-amino-phenyl)-3-{1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]-1h-pyrrol-3-yl}-acrylamide tosylate salt

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731